Upstream Bio raises another $200 million to get through Phase II studies; Samsung Biologics signs $411 million deal with Pfizer to manufacture the drugmaker’s biosimilars portfolio; Pope Francis is in “good general condition” following a three-hour abdominal surgery.
Five things for pharma marketers to know: Thursday, June 8, 2023
New York City air quality suffers from Canadian wildfires; The FDA signals that Leqembi is up for a likely full approval next month; Military officials say the quality of generic drugs is concerning, DoD devising a program to test the safety of widely used medicines.
Five things for pharma marketers to know: Wednesday, June 7, 2023
Merck sues federal government over Medicare drug pricing negotiations; Sanofi and AstraZeneca’s experimental preventive RSV therapy appears to be safe, FDA says; The Apple Watch will track users’ mental health statuses.
Five things for pharma marketers to know: Tuesday, June 6, 2023
Elon Musk’s Neuralink is reportedly worth around $5 billion; Biogen cuts Phase 3 Parkinson’s trial for BIIB122 as part of R&D restructuring; White House considers Mandy Cohen as CDC Director Rochelle Walensky’s successor.
Five things for pharma marketers to know: Monday, June 5, 2023
Novartis’s breast cancer drug Kisqalt reduces the risk of tumors returning by 25%; BioNTech says a cancer immunotherapy candidate it is working on with OncoC4 shrunk tumors in close to 30% of participants in a mid-stage lung cancer trial; Mark Cuban’s Cost Plus Drugs Company is set to compete with AbbVie’s Humira franchise.
Five things for pharma marketers to know: Friday, June 2, 2023
CMS plans to broadly cover a new class of Alzheimer’s drugs pending approval by the FDA; Sandoz is set to move to a new central Basel headquarters by mid-2024; Eikon Therapeutics announced three business development deals and more than $100 million in fresh funding.
Five things for pharma marketers to know: Thursday, June 1, 2023
RA Capital-backed Summation Bio is “terminating operations” next month; Abbott sues former scientist over alleged trade-secret theft; FDA puts clinical hold on PepGen’s myotonic dystrophy type 1 drug.
Five things for pharma marketers to know: Wednesday, May 31, 2023
Atea Pharmaceuticals rejects Tang Capital’s unsolicited takeover bid; Eli Lilly partners with AI-powered drug discoverer Xtalpi in a deal worth up to $250 million; Movement suggests the body, rather than the mind, is the origin of our feelings.
Five things for pharma marketers to know: Tuesday, May 30, 2023
Moderna says it is looking for opportunities in China after confirming that it registered a legal entity there; Walgreens cuts 10% of its corporate workforce; The government’s waiting period for Merck’s $10.8 billion Prometheus Biosciences buyout expired.
Five things for pharma marketers to know: Friday, May 26, 2023
FDA grants full approval to Pfizer’s COVID-19 pill Paxlovid; Illumina shareholders oust board chairman John Thompson; Noom launches an option that will include prescriptions for obesity drugs like Wegovy.